Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Oct 21;16(10):e0259006.
doi: 10.1371/journal.pone.0259006. eCollection 2021.

Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and meta-analysis

Ashutosh Nath Aggarwal  1 , Ritesh Agarwal  1 , Sahajal Dhooria  1 , Kuruswamy Thurai Prasad  1 , Inderpaul Singh Sehgal  1 , Valliappan Muthu  1
Affiliations
Meta-Analysis

Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and meta-analysis

Ashutosh Nath Aggarwal et al. PLoS One. .

Abstract

Objective: The proportion of COVID-19 patients having active pulmonary tuberculosis, and its impact on COVID-19 related patient outcomes, is not clear. We conducted this systematic review to evaluate the proportion of patients with active pulmonary tuberculosis among COVID-19 patients, and to assess if comorbid pulmonary tuberculosis worsens clinical outcomes in these patients.

Methods: We queried the PubMed and Embase databases for studies providing data on (a) proportion of COVID-19 patients with active pulmonary tuberculosis or (b) severe disease, hospitalization, or mortality among COVID-19 patients with and without active pulmonary tuberculosis. We calculated the proportion of tuberculosis patients, and the relative risk (RR) for each reported outcome of interest. We used random-effects models to summarize our data.

Results: We retrieved 3,375 citations, and included 43 studies, in our review. The pooled estimate for proportion of active pulmonary tuberculosis was 1.07% (95% CI 0.81%-1.36%). COVID-19 patients with tuberculosis had a higher risk of mortality (summary RR 1.93, 95% CI 1.56-2.39, from 17 studies) and for severe COVID-19 disease (summary RR 1.46, 95% CI 1.05-2.02, from 20 studies), but not for hospitalization (summary RR 1.86, 95% CI 0.91-3.81, from four studies), as compared to COVID-19 patients without tuberculosis.

Conclusion: Active pulmonary tuberculosis is relatively common among COVID-19 patients and increases the risk of severe COVID-19 and COVID-19-related mortality.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart for study selection.
Fig 2
Fig 2. Proportion of COVID-19 patients also having tuberculosis and corresponding 95% confidence intervals (CI).
Individual proportion estimates are depicted by solid squares, and the corresponding country estimate of annual tuberculosis incidence by hollow circles.
Fig 3
Fig 3. Relative risk, and corresponding 95% confidence intervals (CI), of adverse clinical outcomes among COVID-19 patients having tuberculosis.
See this image and copyright information in PMC

References

    1. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. Intervirology. 2021;64(1):36–47. Epub 2020/12/10. doi: 10.1159/000512592 - DOI - PMC - PubMed
    1. Chidambaram V, Tun NL, Haque WZ, Majella MG, Sivakumar RK, Kumar A, et al. Factors associated with disease severity and mortality among patients with COVID-19: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241541. Epub 2020/11/19. doi: 10.1371/journal.pone.0241541 - DOI - PMC - PubMed
    1. Dorjee K, Kim H, Bonomo E, Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One. 2020;15(12):e0243191. Epub 2020/12/08. doi: 10.1371/journal.pone.0243191 - DOI - PMC - PubMed
    1. Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362. Epub 2020/07/30. doi: 10.1111/eci.13362 - DOI - PubMed
    1. Javanmardi F, Keshavarzi A, Akbari A, Emami A, Pirbonyeh N. Prevalence of underlying diseases in died cases of COVID-19: A systematic review and meta-analysis. PLoS One. 2020;15(10):e0241265. Epub 2020/10/24. doi: 10.1371/journal.pone.0241265 - DOI - PMC - PubMed